Foresite Capital Management IV, LLC bought $1000K of Eikon Therapeutics (EIKN)
Executed Feb 4, disclosed Feb 7, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 6), the stock returned -2.0% (delay-adjusted); from the execution session (Feb 5), -15.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
Foresite Capital Management IV, LLC (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Eikon Therapeutics, Inc. (EIKN). Across 1 priced purchase filing, the average 21-session return was -15.7% from execution and -2.0% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of EIKN (55,555 sh × $18.00, as filed), executed Feb 4.
Healthcare · Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→